Novo Nordisk stock tumbled Friday — pulling Corbus Pharmaceuticals into a steep dive — after its new approach to weight loss caused neuropsychiatric side effects.Please watch the video at ...

This post was written by Melanie Riehl BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best biotech plays outside of the GLP-1 ...

Check the time stamp on this data. Updated AI-Generated Signals for Global Partners Lp Representing Limited Partner Interests ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

The GLP-developed warehouses were disposed of due to "the stabilised nature of the portfolio, its attractive quality and ...

Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO market in 2024, which analysts touted as a comeback year for public offerings. The Richmond, California-based company ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Financial stocks rose in late Friday afternoon trading, with the NYSE Financial Index adding 0.5% and the Financial Select Sector SPDR Fund (XLF) up 0.3%. The Philadelphia Housing Index climbed 2.6%, ...

At Fierce Healthcare, we keep track of all the venture capital being funneled into the health tech and digital health ...

(Reuters) - Investment firm Ares Management Corp is in advanced talks to acquire GLP Capital Partners' operations outside China, Bloomberg News reported on Friday, citing people familiar with the ...

Ares Management is in advanced talks to acquire GLP Capital Partners' non-China operations in a deal potentially worth $5B, ...